The emerging role of solifenacin in the treatment of overactive bladder

Bibliography

• STEWART WF, COREY R, HERZOG AR iet al: i Prevalence of overactive bladder in women: results from the NOBLE program. iInt. Urogynaecol J. i (2001) 12(3):S66.
   Google Scholar
• •A large-scale postal questionnaire epidemiological study examining the incidence of OAB in men and women in the US.
   Google Scholar
• MILSOM I, ABRAMS P, CARDOZO L, ROBERTS RG, THUROFF J, WEIN AJ: How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. iBIU Int. i (2001) 87(9):760–766.
   Google Scholar
• ABRAMS P, CARDOZO L, FALL M, GRIFFITHS D, ROSIER P, ULMSTEN U iet al: i The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society. iNeurourol Urodyn. i (2002) 21:167–178.
   Google Scholar
• •This is a concensus document published by the International Continence Society (ICS) reviewing the current terminology of lower urinary tract dysfunction.
   Google Scholar
• ANDERSSON K-E: The overactive bladder. Pharmacologic basis of drug treatment. iUrology i (1997) (6A Suppl.):74–84.
   Google Scholar
• CAULFIELD MP, BIRDSALL NJ: International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. iPhannacol Rev. i (1998) 50:279.
   Google Scholar
• YAMAGUCHI 0, SHISIDA K, TAMURA K iet al.: i Evaluation of mRNAs encoding muscarinic receptor subtypes in human detrusor muscle.' iUrol. i (1996) 156:1208.
   Google Scholar
• HARRIS DR, MARSH KA, BIRMINGHAM AT iet al.: i Expression of muscarinic M3receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. iJ. Urol. i (1995) 154:1241.
   Google Scholar
• HEDGE SS, CHOPIN A, BONHAUS D iet al.: i Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats iin vitro i and iin vivo. Br. I Pharinacol i (1997) 120:1409.
   Google Scholar
• HEGDE SS, EGLEN RM: Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. iLife Sci. i (1999) 64:419.
   Google Scholar
• BRAVERMAN AS, RUGGIERI MR: The M2 receptor contributes to contraction of the denervated rat urinary bladder. Am. iJ. Physiol i (1998) 275:1654.
   Web of Science ®Google Scholar
• IKEDA K: Affinity of YM905 and Oxybutynin for various neurotransmitter receptors and ion channels. Yamanouchi Expert Op/n. lnvestig. Drugs (2004) 13(10) i b1347 b Pharmaceutical Co. Ltd (1998). Registration No. D9801968-1. International Study ID:905-PH–001.
   Google Scholar
• IKEDA K: Affinity of YM905 for human muscarinic Ml, M2 and M3 receptors. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803214-02.00. International Study ID:905-PH–002.
   Google Scholar
• SUZUKI M: Inhibitory effect of YM905 on carbachol-induced contraction of guinea pig urinary bladder. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D9803231-1. International Study ID:905-PH–007.
   Google Scholar
• IKEDA K, KOBAYASHI S: Effects of YM905, Oxybutynin and Darifenacin on carbachol induced intracellular calcium mobilization by dispersed longitudinal smooth muscle cells of guinea pig colon. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803320-02.00. International Study ID:905-PH–006.
   Google Scholar
• IKEDA K, KOBAYASHI S: Effects of YM905, tolterodine and Oxybutynin on M3 receptor mediated cytosolic free Ca2+ mobilization in acutely dissociated cells of guinea pig urinary bladder smooth muscle and murine submandibular gland. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D199803217-02.000. International Study ID:905-PH–005.
   Google Scholar
• IKEDA K: Effect of YM905 on response of urinary bladder and salivary gland to carbachol in anesthetised mouse. (1998) Registration No: D199803215-02.00. International Study ID:905-PH–010.
   Google Scholar
• SAITOH C, IIZUMI Y: Effect of YM-67905 on micturition reflex in anesthetised rats. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No. D9802853-1. International Study ID:905-PH–011.
   Google Scholar
• IKEDA K: Effect of chronic doses of YM905 on carbachol induced salivary secretion in mice. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D199803318-02.00. International Study ID:905-PH–020.
   Google Scholar
• KATZ IR, SANDS LP, BILKER W, DIFILIPPO S, BOYCE A, D'ANGELO K: Identification of medication that cause cognitive impairment in older people: the case of oxybutynin chloride. ./. Am. iGeriatr. Soc. i (1998) 46:8–13.
   PubMed Web of Science ®Google Scholar
• YANAGIHARA T: Plasma concentrations of the unchanged drug after repeated oral administration of YM905 to dogs. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9803132-1. International Study ID:905-ME–004.
   Google Scholar
• YANAGIHARA T: Plasma concentrations of the unchanged drug and its metabolite BY-348C after single intravenous and oral administration of YM905 to rats. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9802939-1. International Study ID:905-ME–002.
   Google Scholar
• YANAGIHARA T: Plasma concentrations of the unchanged drug after single intravenous and oral administration of YM905 in dogs. Yamanouchi Pharmaceutical Co. Ltd (1998). Registration No.D9802940-1. International Study ID:905-ME–003.
   Google Scholar
• YANAGIHARA T: iIn vitro i plasma protein binding of YM905. Yamanouchi Pharmaceutical Co Ltd (1998). Registration No. D199803314-02.00. International study ID:905-ME–007.
   Google Scholar
• YANAGIHARA T:Comparison of iin vitro i metabolic patterns of YM905 among various species. Yamanouchi Pharmaceutical Co Ltd (1998). Registration No.D9803351-1. International study ID:905-ME–009.
   Google Scholar
• ONDERWATER RCA: Identification of human liver CYP isoforms involved in the metabolism of YM905. Yamanouchi Europe By. (1999) Registration No: D199900072-01.00 International Study ID:905-ME–020.
   Google Scholar
• NAKAMURA E: Absorption, distribution, metabolism and excretion of radioactivity after oral administration of MC-YM905 to rats. Yamanouchi Pharmaceutical Co Ltd (1997) Registration No: D9802237-1 International Study ID:905-ME–001.
   Google Scholar
• CHAPPLE CR, ARANO P, BOSCH JL, DE RIDDER D, KRAMER AE, RIDDER AM: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase 2 dose-finding study. iBIU Int. i (2004) 93(1):71–77.
   Google Scholar
• CHAPPLE CR, RECHBERGER T, AL-SHUKRI S iet al.: i Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. iBIU Int. i (2004) 93(3):303–310.
   Google Scholar
• VAN APLEN WW: A double blind, randomised, placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. YEU. (1998) Registration No. D9801421-1. International Study ID:905-CL–002.
   Google Scholar
• FUDER H: A double blind, randomised, placebo controlled rising study in elderly male and female volunteers to evaluate safety, tolerability and pharmacokinetics of multiple dosing with YM905. Yamanouchi Europe BV. Registration No: D9803294-1. International Study ID:905-CL–004.
   Google Scholar
• VAN APLEN WW: A placebo controlled dose rising study in healthy male volunteers to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of single oral dosages of YM905. Clinical Pharmacology Research Department, Yamanouchi Europe BV. (1998). Registration No: D200001570-01.00. International Study ID:905-CL–001.
   Google Scholar
• DIXON RIVI: Effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of YM905 administered orally in healthy male and female volunteers. Covance Clinical Research Unit, Inc. (2001). International Study ID:905-CL–010.
   Google Scholar
• HEGER-MAHN D: A double-blind, placebo controlled, cross over pharmacokinetic interaction of steady state YM905 and steady state oral contraceptive in healthy female volunteers. Yamanouchi Europe BV. International Study ID:905-CL–011.
   Google Scholar
• KELLEHER CJ, CARDOZO LD, KHULLAR V, SAL VATORE S: A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. iBr. J. Obstet. Gynaecol. i (1997) 104:988–993.
   Web of Science ®Google Scholar
• •This was a follow-up study of women with detrusor overactivity who were prescribed antirnuscarinic therapy. At follow up 20% were still taking regular medication with adverse events were reported as the main reason for discontinuation. Affiliation
   Google Scholar